Symple Surgical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Symple Surgical is a medical device startup pioneering controlled microwave ablation technologies for interventional gastroenterology and cardiology. Its lead product, the GRIZZLY Microwave Ablation System, is designed for the automated treatment of Barrett's Esophagus to prevent progression to esophageal adenocarcinoma. The company also has a development-stage renal denervation system for hypertension and is led by serial entrepreneur Dan Kasprzyk, with operations in Sacramento, CA, and Flagstaff, AZ. Symple Surgical is pre-revenue and privately held, backed by a team and advisors with extensive medical device experience.

GastroenterologyCardiology

Technology Platform

Proprietary controlled microwave ablation platform utilizing high-frequency energy (18GHz & 2.45GHz) for depth-specific, automated tissue ablation. Key features include compliant balloon catheters, self-centering antennas, real-time temperature monitoring, active cooling, and antennae capable of both emitting and receiving signals for potential feedback.

Opportunities

The large and growing population with Barrett's Esophagus, coupled with reported limitations of current radiofrequency ablation, creates a significant addressable market for a more effective microwave ablation system.

The recent FDA approvals in the renal denervation space have revitalized a multi-billion dollar market for resistant hypertension, providing a clear regulatory pathway and commercial opportunity for a differentiated technology.

Risk Factors

The company faces substantial clinical risk as its technologies are unproven in human trials and must demonstrate superiority to established standards.

As a small, pre-revenue private company, it is highly dependent on securing ongoing funding to finance development and faces formidable commercialization challenges against large, entrenched competitors in its target markets.

Competitive Landscape

In Barrett's Esophagus ablation, the primary competitor is radiofrequency ablation (RFA) systems, such as the Barrx™ from Medtronic. In renal denervation, the market is now served by approved radiofrequency (Medtronic's Symplicity Spyral) and ultrasound (Recor Medical's Paradise) systems from large medtech players. Symple Surgical's microwave approach must prove clinical advantages to gain share.

More companies in Drug Delivery & Formulation →More companies in United States →